OncoMatch/Clinical Trials/NCT07871838
Safety, Efficacy and Quality of Life After Adjuvant Hypofractionated Radiotherapy for Endometrial Cancer
Official title: Hypofractionated Endometrial Radiation Outcomes and Safety
Is NCT07871838 recruiting? Yes, currently enrolling (Oct 2026). This NA trial studies non-drug interventions for endometrial cancer.
Clinical experience with hypo fractionated radiotherapy to date has shown that it is a safe and effective way to treat many types of cancer. Hypo fractionation means that the patient receives a total of 5 radiation treatments every other day, rather than 25 treatments over 5 weeks. The goal of this study is to find out how safe this special kind of radiation technique is for women with endometrial cancer, both right after the treatment and later on. We also want to see how well this treatment works in stopping the cancer from coming back and how it affects the patients' overall health and quality of life. The main question it aims to answer is: How does this particular type of radiotherapy affect the patients in terms of short and long term side effects? Participants will: * Visit the clinic for a total of 15 times in 60 months for check ups * Complete a total of 9 questionnaires throughout the 15 visits * Have standard-of-care blood tests and imaging to monitor the cancer response to treatment
Check if I qualifyExtracted eligibility criteria
Cancer type
Endometrial Cancer
Disease stage
Required: Stage FIGO 2009 STAGE I, FIGO 2009 STAGE II, FIGO 2009 STAGE IIIA, FIGO 2009 STAGE IIIB, FIGO 2009 STAGE IIIC1 (other)
Excluded: Stage PARA-AORTIC NODAL DISEASE
FIGO 2009 stage I-IIIC1 are eligible. Para-aortic nodal disease [excluded].
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: surgery (total hysterectomy + bilateral salpingo-oophorectomy + sentinel lymph node biopsy or pelvic nodal dissection)
Patients will have had previous total hysterectomy + bilateral salpingo-oophorectomy + sentinel lymph node biopsy or pelvic nodal dissection, will be fully debulked (R0 resection)
Cannot have received: non-standard surgery
Non-standard surgery
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07871838 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior non-standard surgery disqualifies patients from enrollment.
What disease stage is eligible?
Stage FIGO 2009 STAGE I or FIGO 2009 STAGE II or FIGO 2009 STAGE IIIA or FIGO 2009 STAGE IIIB or FIGO 2009 STAGE IIIC1 is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages